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Abstract 
Background.  The success of transplantation is hampered by rejection of the 
graft by alloreactive T cells.  Donor dendritic cells (DC) have been shown to be 
required for direct priming of immune responses to antigens from MHC 
mismatched grafts.  However, for immune responses to MHC matched, minor H 
antigen mismatched grafts the magnitude of the T cell response to directly 
presented antigens is reduced, and the indirect pathway is more important.  
Therefore we aimed to investigate the requirement for donor DC to directly 
present antigen from minor H antigen mismatched skin and hematopoietic grafts. 
Methods. Langerhans cell (LC)- or conventional (c)DC-depleted skin or 
hematopoietic cells from male DC-specific diphtheria toxin receptor (DTR) mice 
were grafted onto, or injected into, syngeneic female recipients, and survival of 
the male tissue was compared with non-depleted tissue.  Activation of the 
alloreactive immune response was tracked by the expansion of T cells specific 
for male HY-derived epitopes.  
Results.  Our data demonstrate that depletion of donor LC, dermal cDC, or both 
from skin grafts prolongs their survival, but does not prevent rejection. Extended 
survival correlates with delayed expansion of HY peptide-specific CD8+ T cells.  
In addition depletion of donor cDC delays rejection of male hematopoietic cells.  
Conclusions.  Our results demonstrate for the first time that direct presentation 
of minor H antigens by donor DC is required for efficient rejection of skin and 
hematopoietic grafts by CD8+ T cells.  But, in the absence of donor DC, indirect 
presentation of minor antigens is sufficient to mediate the response. 
Introduction 
Transplantation is the only curative option for end stage organ failure and is an 
effective approach for the treatment of haematological malignancy.  The main 
barrier to this approach is allograft rejection directed against antigens encoded in 
the major histocompatibility complex (MHC) (1).  Transplant rejection also takes 
place between MHC matched individuals, where the minor histocompatibility (H) 
antigens, peptides derived from polymorphic self-proteins differing between 
donor and recipient and presented by MHC class I and II molecules, stimulate an 
immune response leading to rejection of the allograft (2, 3). 
 
Alloantigen recognition and activation of graft-specific T cells occurs by three 
mechanisms.  In the direct pathway intact donor MHC molecules expressed on 
graft-associated antigen presenting cells (APC) are recognized by host T cells.  
The high frequency of naïve T cells specific for allogeneic MHC molecules has 
led to the suggestion that the direct pathway mediates acute rejection of MHC 
mismatched grafts (4, 5).  Alternatively, in the indirect pathway, recipient APC 
process graft-derived material and present peptides to alloreactive host T cells 
(6, 7).  Indirect allospecific T cells have a lower precursor frequency and this 
response is thought to become more important once donor APC are lost from the 
graft, thereby mediating chronic rejection of grafted tissue.  Finally, in semi-direct 
allorecognition host APC acquire intact MHC:peptide complexes from donor cells 
(6).   
 
Dendritic cells (DC) are professional APC, required to prime and control T cell 
responses.  The role of donor DC in rejection of MHC mismatched grafts has 
been explored by grafting tissue into an intermediate host under 
immunosuppression, followed by re-transplantation of the now passenger cell-
depleted graft to a secondary recipient.  Using this approach, MHC mismatched 
kidney grafts were accepted indefinitely (8), while heart graft survival was 
prolonged (9).  In addition, use of Flt3 ligand deficient donors, which are severely 
depleted of DC and other immune cells, prolonged survival of MHC mismatched 
heart grafts (10).  Transfer of donor DC into such transplant recipients was 
sufficient to initiate graft rejection (8).  Therefore, these data suggest that donor 
DC are required for direct presentation of alloantigens from MHC mismatched 
grafts.  
 
For MHC mismatched grafts, the high frequency of T cells recognizing allogeneic 
MHC accounts for the importance of the direct pathway of antigen presentation.  
In contrast, minor H antigen disparate grafts share MHC molecules with the 
recipient, that differ only by a limited set of bound self-peptides.  Consequently, 
the magnitude of the direct response is expected to be markedly reduced in 
comparison with MHC mismatched grafts (3).  The indirect pathway was first 
described in the context of minor H antigens (11) where it operates efficiently 
(12).  It is therefore of interest to investigate whether direct presentation of 
alloantigen by DC is still required following transplantation of minor H 
mismatched grafts.   
 Here, we have investigated the requirement for donor DC for the priming of skin 
and haematopoietic graft rejection immune responses mediated by the male-
specific minor H antigen, HY.  Identification of the HY peptide epitopes presented 
by the H2b MHC haplotype has facilitated the analysis of this immune response 
(12).  In particular, MHC class I HY-specific tetramers can be used to quantify the 
CD8 T cell response.  To examine the role of graft-resident DC we have used 
DC-specific diphtheria toxin receptor (DTR) mice for in vivo ablation of defined 
DC populations from skin and haematopoietic cell grafts prior to transplantation 
(reviewed in 13).  In this approach, cell-type specific expression of the high 
affinity, primate DTR renders these cells uniquely susceptible to killing by 
diphtheria toxin (DT).  Further, the receptor is a fusion protein with GFP allowing 
identification of expressing cells and monitoring of their depletion by flow 
cytometry.  As mouse cells do not otherwise express a high affinity DTR, cell 
depletion is restricted to the tissue expressing the DTR gene.  Endocytosis of the 
toxin rapidly blocks protein synthesis initiating apoptosis of both mitotic and 
terminally differentiated cells.  To direct DTR expression to specific DC subsets, 
the CD11c and Langerin promoters have been used (13). Using this approach, 
we demonstrate that direct presentation by donor DC is required to elicit the most 
rapid rejection of minor H antigen mismatched skin and haematopoietic grafts. 
Results 
Depletion of cDC or Langerin+ DC from skin grafts delays their rejection. 
To address the role of donor DC in transplant rejection we grafted skin from male 
donors, that had or had not been depleted of different DC populations, onto 
female recipients.  Donor skin contains three major populations of DC: 
Langerhans cells (LC) in the epidermis; and Langerin+ and Langerinneg CD11c+ 
conventional (c)DC populations in the dermis (14, 15). In initial experiments we 
investigated whether donor dermal cDC were required for the rejection of minor 
H alloantigen (HY) mismatched skin grafts by using CD11c-DTR mice to 
specifically deplete CD11chi cDC.  In these transgenic mice a high affinity DTR is 
expressed from the CD11c promoter, rendering CD11chi DC sensitive to killing by 
DT (13, 16).  Figure 1A shows the splenic, GFP+, CD11c+ cDC present in 
untreated CD11c-DTR mice.  Panel B shows that a single injection of DT 
routinely depletes 80-90% of systemic cDC, which has previously been shown to 
include dermal cDC (17).  DT was injected into wild type (wt) or CD11c-DTR / 
C57BL/6 male mice and 24 hours later the mice were sacrificed and their skin 
grafted onto syngeneic female recipients.  Female mice receiving grafts from wt 
males injected with DT rejected the grafts after approximately 30 days as 
published, (Figure 2A; median survival time for 50% of the grafts 26.5 days (18)), 
demonstrating that treatment of the graft with DT does not alter rejection in this 
model.  However, depletion of cDC from the graft significantly prolonged survival 
(Figure 2A; median survival for 50% of the grafts 41 days).  
 
Epidermal LC are not depleted from CD11c-DTR mice due to their low level 
expression of CD11c in situ (13).  Therefore, to address whether LC and 
Langerin+ DC were required for rejection of male skin grafts we repeated our 
experiments using skin from male Langerin-DTR mice injected with DT 24 hours 
previously. The right panel of Figure 1A shows the epidermal GFP+, CD11b+ LC 
present in untreated Langerin-DTR mice.  Figure 1C shows that a single injection 
of DT efficiently depletes Langerin+ DC from these mice (19, 20). Figure 2A 
demonstrates that depletion of Langerin+ DC also significantly prolongs survival 
of male syngeneic skin grafts (median survival time for 50% of the grafts 41 
days).  This was equivalent to the time required to reject cDC-depleted male skin 
from female recipients. 
 
Collectively these data demonstrate that individual donor DC populations are not 
required for the rejection minor H antigen mismatched skin, but that activation of 
the rejection response is less efficient in their absence.  The observation that 
depletion of either CD11chi cDC or Langerin+ DC delays rejection to the same 
extent suggested that there was redundancy in the requirement for different skin 
DC populations to activate an optimal anti-graft response.  To address this 
hypothesis, we transplanted skin from DT-injected male CD11c-DTR x Langerin-
DTR mice that were depleted of both cDC and Langerin+ DC (Figure 1B and C).  
Figure 2B shows that depletion of all cutaneous DC again resulted in prolonged 
survival of skin grafts (median survival time for 50% for the grafts 44.5 days), but 
that the grafts were ultimately rejected with the same kinetics as those depleted 
of either cDC or Langerin+ DC.  Therefore, these data demonstrate that depletion 
of cutaneous DC from donor skin delays, but cannot prevent, rejection of male 
syngeneic grafts.  
 
Reduced expansion of donor-specific T cells in mice receiving DC-depleted 
skin grafts. 
The prolonged acceptance of donor DC-depleted skin grafts suggested that male 
graft-specific T cell responses were not efficiently activated in the absence of 
donor DC.  We have previously defined the Uty peptide as a dominant MHC I-
restricted minor H antigen that provokes allograft rejection in C57BL/6 male to 
female grafts (21).  Therefore, to investigate whether Uty-specific T cells were 
activated in mice receiving DC-depleted grafts we examined expansion of CD8+ 
HYDb Uty tetramer+ cells in the blood of female recipients at the peak of the T cell 
response, 2 weeks after grafting (21).  Figure 3 shows that there is a significant 
reduction in the expansion of HYDb Uty+ CD8+ T cells in mice that have received 
grafts depleted of either cDC or LC.  Therefore these data demonstrate that 
prolonged graft survival in mice receiving DC-depleted grafts is associated with a 
reduction in the priming of allograft-specific T cells. 
 
To investigate whether the delayed rejection of DC-depleted skin grafts reflected 
altered kinetics for the activation of the male-specific T cell response, we also 
measured expansion of HYDb Uty+ CD8+ T cells 30 days after grafting.  As shown 
in Figure 4, there is no difference in the accumulation of HYDb Uty+ tetramer+ T 
cells at this time point in any of the groups.  Collectively these data demonstrate 
that in the absence of donor cDC or Langerin+ DC, graft-specific T cells are 
primed with slower kinetics, which results in the prolonged survival but ultimate 
rejection, of minor H antigen mismatched allografts. 
 
Depletion of cDC delays rejection of hematopoietic grafts. 
The role of donor skin DC in direct presentation of graft-derived antigens will 
depend on the establishment of lymphatic and vascular vessels that allow DC to 
leave the tissue.  Therefore, we investigated whether donor DC were required to 
prime the rejection response in a hematopoietic transplant model that did not 
depend on graft vascularization.  Wt or CD11c-DTR male mice were injected with 
DT and 24 hours later splenocytes isolated, labeled with CFSE and injected, 
along with control female cells labeled with a different dose of CFSE, into female 
recipients.  In this model, the male splenocytes activate the immune response 
and subsequently act as targets of cytotoxic CD8 T cells (22, 23).  Figure 5A 
shows that in vivo cytotoxicity is significantly reduced 10 days after immunization 
of female mice with cDC-depleted male splenocytes.  However, at this time, 
HYDb Uty+ tetramer+ T cells have expanded to the same extent in both groups 
(Figure 5B).  In accord with this observation, by 20 days post-injection, male 
targets are efficiently killed in both the cDC-depleted and non-depleted groups 
(Figure 5C).  Together these data show that direct presentation of minor H 
antigens by donor DC contributes to the rejection process by augmenting HY-
specific cytotoxic T cell responses, but is not required for activation of these 
minor H allospecific T cells.  
Discussion 
Donor DC are thought to be required for acute rejection of MHC-mismatched 
transplants, following direct presentation of alloantigens to T cells in lymphoid 
organs draining the grafted tissue (24).  However, unlike the high frequency of 
alloreactive T cells directly recognizing MHC disparate graft antigens, the 
frequency of T cells specific for directly presented minor H antigens is very low.  
This will potentially limit the efficacy of the direct pathway, and whether donor DC 
are important for rejection of minor H antigen mismatched grafts is not known.  
To investigate this question we have exploited inducible models of DC depletion 
to transplant male DC-depleted skin or splenocytes to female, DC-replete, 
recipients.  We have shown that neither CD11c+ dermal cDC nor Langerin+ DC 
are required for the rejection of HY minor H antigen mismatched skin grafts by 
female recipients.  But, in the absence of either or both of these groups of skin 
DC, graft rejection is significantly delayed due to a reduction in priming of HY-
specific CD8+ T cells.  The lower frequency of HY alloantigen-specific T cells, 
and the requirement for recipient DC to take up and process cells released by the 
graft, indicate that the kinetics of priming of indirect allospecific T cell responses 
will be slower than that of the direct pathway.  Therefore, our results suggest a 
model in which direct presentation by donor DC is required for the efficient 
rejection of minor H antigen mismatched grafts, but that indirect priming of CD8+ 
T cells by recipient DC is sufficient to mediate a delayed response.  This model is 
in agreement with data from McKay et al, who demonstrated prolonged survival 
of minor H antigen mismatched skin from mice in which donor DC are not 
activated to migrate out of the graft to directly prime T cells in draining LN (25).  
 
An alternative model would suggest that indirect presentation of minor H antigens 
is the dominant mode of graft rejection, but donor DC migrating out of the graft 
may provide a more rapid source of alloantigen to be processed by LN-resident 
recipient DC than other donor cell types.  This second model is in accordance 
with previous data showing that indirect recognition of graft antigens is sufficient 
to mediate rejection of MHC mismatched skin (26, 27).  In order to distinguish 
between the two models we investigated the priming of HY-specific T cells in 
females receiving male, cDC-depleted haematopoietic cells.  In this system 
alloantigen is abundantly available for indirect presentation by recipient DC within 
the spleen, and active trafficking of DC from the graft to lymphoid organs is not 
required to prime the response.  Therefore, if donor DC only provided more rapid 
access to antigens for indirect presentation to LN T cells, depletion of donor DC 
would not be predicted to alter priming of the T cell response in this second 
model.  We show that transfer of cDC-depleted splenocytes results in expansion 
of HY-specific CD8+ T cells, but that these T cells do not initially acquire effector 
function, and male target cells are only partially rejected.  However, as with mice 
receiving DC-depleted skin grafts, rejection of male splenocytes is complete but 
delayed in mice injected with cDC-depleted cells.  Therefore, these data support 
the first model in which direct presentation by donor DC is an important 
mechanism for efficient rejection of minor H antigen mismatched transplants.  
But, indirect presentation by recipient APC is sufficient to mediate the response 
and, in the case of skin grafts, we cannot exclude a contribution from migrating 
DC in providing antigen for indirect presentation by host LN DC.  Furthermore, 
our data demonstrate that the direct pathway is important for the rapid rejection 
of male to female grafts, despite the reduced precursor frequency of T cells 
specifically recognizing directly presented minor H antigens.  
 
The LC paradigm states that activated LC migrate from the skin to prime T cell 
immunity in draining LN.  LC which have acquired antigen in the skin migrate to 
draining LN (28), but recent experiments in virally-infected mice have shown that 
LC are not required to prime the CD8 T cell response.  Consequently the role of 
LC in skin immunity remains unclear (reviewed in 29).  LC initiate host versus 
graft reactivity in murine MHC mismatched bone marrow (bm) chimeras (30), and 
have classically been assumed to prime immune responses to skin grafts (31).  
However, it has previously been shown that male skin from mice constitutively 
depleted of epidermal LC is more rapidly rejected from female recipients than wt 
LC-replete skin showing, in agreement with our data, that LC are not required for 
rejection of minor antigen mismatched skin grafts (32).  However, the authors 
were not able to demonstrate a difference in T cell priming in this model, 
probably due to an inability to track antigen-specific T cells.  The differences in 
the kinetics of graft rejection of LC-depleted skin between our data and that of 
Obhrai et al may be due to differences in the LC-depletion model used (32, 33).  
Unlike Langerin-DTR mice, from which LC can be inducibly depleted, the 
Langerin-DTA mice used by Obhrai et al constitutively lack LC from birth.  These 
mice tend to display hyperimmune responses that are not seen when LC are 
transiently depleted from Langerin-DTR mice (28, 34).  An alternative explanation 
is that we deplete both epidermal LC and dermal Langerin+ DC from our donor 
skin compared to only LC in the DTA model (32).  Our observation that skin 
depleted of all cutaneous DC was rejected with the same kinetics as skin 
depleted of either Langerin+ DC or cDC suggests that a single donor DC 
population does not dominate priming of the skin graft rejection response.  
Furthermore, these data demonstrate that either the low precursor frequency for 
T cells recognizing directly presented minor H antigens limits the importance of 
the direct immune response, which will always be dominated by indirectly primed 
T cells, and/or that the reduced efficiency of depletion of cDC and LC from 
CD11c-DTR x Langerin-DTR mice compared to the single DTR mice (Figure 1), 
results in persistence of sufficient donor DC to directly prime a sub-optimal T cell 
response.   
 
In conclusion, we have demonstrated that removal of donor DCs from skin and 
hematopoietic cell grafts weakens the host versus graft (HvG) CD8+ T cell 
response to minor H antigens.  For HLA matched bm transplants, minor H 
antigens are main targets of both the graft versus host (GvH) and HvG 
responses.  To maintain the benefit of the graft versus leukemia (GvL) effect, the 
component of the GvH response with specificity for hematopoietic cells (35), it is 
important to develop practical strategies that target solely the HvG response.  In 
similar fashion to our findings with mouse hematopoietic cell grafts, depletion of 
DCs from human bm grafts would be expected to reduce the severity of the HvG 
response by limiting antigen presentation via the direct pathway without 
influencing the GvL response.  Weakening the intensity of the HvG response by 
DC depletion may form a useful adjunct for strategies designed to induce graft 
specific tolerance such as intranasal (22) or sub-cutaneous (36) delivery of 
recipient specific minor H antigen peptide epitopes. 
 
 
Materials and Methods. 
Mice and DC depletion models  
Animals were used under protocols approved by local institutional research 
committees, in accordance with U.K. Home Office guidelines.  C57BL/6 female 
mice (6-8 weeks) were purchased from Harlan Orlac (Bicester, UK).  CD11c-DTR 
mice were bought from Jackson Laboratories (USA).  Langerin-DTR mice were 
kindly provided by A. Kissenpfennig and B. Malissen (37).  Both lines were bred 
in the Comparative Biology Unit at UCL.  Both CD11c-DTR and Langerin-DTR 
mice have been back-crossed onto C57BL/6 backgrounds for more than 10 
generations.  24 hours before sacrifice of mice for grafting, CD11c-DTR and 
Langerin-DTR males were injected i.p. with 100ng or 500ng of DT (Sigma) in 
PBS, to deplete cDC or Langerin+ DC respectively (16, 19).  Control C57BL/6 
males were also injected with 100ng DT.  To deplete both cDC and Langerin+ DC 
CD11c-DTR mice were crossed with Langerin-DTR mice for one generation.  
Langerin-DTR x CD11c-DTR mice were injected with 100ng DT. 
 
Flow cytometry and antibodies 
The following antibodies were used: CD11c-PE (N418; Miltenyi Biotec.); CD11b-
APC (M1/70; eBiosciences), CD8-PerCP or CD8-APC (53.6-7; BD Pharmingen 
or eBiosciences).  Samples were acquired using a FACSCalibur flow cytometer 
(BD Bioscience), and analyzed using FlowJo software (Treestar). 
  
Skin grafting 
Skin grafting was conducted as described previously (38) and after removal of 
the plaster casts, the grafts were observed every two days.  Grafts were read in 
coded groups and were scored as being rejected when <10% viable tissue was 
visible.  
 
Tetramer staining 
Peripheral blood lymphocytes (PBL) were prepared by collection of tail blood into 
heparin, followed by brief lysis of red blood cells in water.  Samples were 
resuspended in 50l RPMI/10% FBS in a 96-well plate and incubated with 0.25l 
HYDb Uty-PE tetramer (Proimmune, Oxford) for 20 min. at 37C.  Anti-CD8 
antibody was subsequently added to the wells and the cells incubated at 4C for 
15 minutes, before washing and resuspension in PBS/1% FBS for analysis. 
 
Immunization and in vivo cytotoxicity assays 
Splenocytes were isolated from wt C57BL/6 and CD11c-DTR male mice that had 
been injected with DT 24 hours previously.  Control splenocytes were also 
isolated from female C57BL/6 mice.  Target male cells were labeled with low 
dose (0.5M) CFSE and mixed at a 1:1 ratio with female control cells labeled 
with high dose (5M) CFSE.  A total of 107 cells were injected i.v. into female 
C57BL/6 recipients.  At defined time points PBL or splenocytes were analyzed by 
flow cytometry for the presence of the 2 populations of CFSE-labeled cells.  
Specific lysis was calculated, in comparison to the ratio of male:female cells 
injected into recipient mice according to the equation:  
1  (female:male injection mix)       x100 
      (female:male imm. recipient) 
 
Statistical analysis 
The Mann-Whitney U test was used for most statistical analyses.  Statistical 
analysis of graft survival was by the log-rank method.  A p value of 0.05 was 
regarded as significant. 
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Figure legends. 
Figure 1. Depletion of DC from donor mice. 
Donor male wt, CD11c-DTR and Langerin-DTR mice were injected with DT 24 
hours prior to harvesting skin for grafting.  Depletion of the relevant DC 
population was determined by flow cytometry.  GFP expression is shown on the 
X axis and staining for CD11b and CD11c as indicated on the Y axes.  A. Left 
panel shows the splenic GFP+, CD11c+ cDC population of a representative 
untreated CD11c-DTR mouse.  The right panel shows the epidermal GFP+, 
CD11b+ LC population of a representative untreated Langerin-DTR mouse.  The 
boxed regions show the gating strategy applied in B and C for GFP+ cDC or LC 
from CD11c-DTR or Langerin-DTR mice respectively.  B. The left plot shows the 
splenic CD11c+ population (cDC) of a representative wt C57BL/6 mouse injected 
with DT.  The middle and right plots show depletion of cDC from the spleens of 
representative CD11c-DTR and CD11c-DTR x Langerin-DTR mice.  C. The left 
plot shows the skin epidermal CD11b+ population (LC) of a representative wt 
C57BL/6 mouse injected with DT. The middle and right plots show depletion of 
LC from the spleens of representative Langerin-DTR and CD11c-DTR x 
Langerin-DTR mice.  
 
Figure 2. Depletion of either cDC or LC delays rejection of syngeneic male grafts 
from female mice. 
Graft survival of syngeneic male grafts placed on C57BL/6 females.  A. Donor 
male wt, CD11c-DTR and Langerin-DTR mice were injected with DT 24 hours 
prior to harvesting skin for grafting.  The Kaplan-Meier plot is shown from 1 of 2 
independent experiments: wt n=6, CD11c-DTR n=9, Langerin-DTR n=9.  Log-
rank analysis p = <0.0001.  B. Grafts from CD11c-DTR x Langerin-DTR mice that 
had been depleted of both cDC and Langerin+ DC 24 hours before grafting.  
Kaplan-Meier plot: wt n=7, CD11c-DTR x Langerin-DTR n=8.  Log-rank analysis 
p = 0.0013. 
 
Figure 3. Reduced expansion of HYDb Uty-specific CD8+ T cells in mice grafted 
with cDC- or Langerin+ DC-depleted skin. 
Expansion of male-specific HYDb Uty-specific CD8+ T cells in the blood of female 
mice 13-19 days after receiving control skin grafts (+ DT), or grafts depleted of 
cDC or Langerin+ DC.  Data are pooled from 2 independent experiments.  
Symbols represent individual mice, bars show the mean percentage of CD8+ 
HYDb Uty+ cells. ** p = <0.01, * p = <0.05. 
 
Figure 4. Expansion of antigen-specific CD8 T cells at later time points in mice 
grafted with DC-depleted skin. 
Expansion of male-specific HYDb Uty-specific CD8+ T cells in the blood of female 
mice 30 days after receiving control skin grafts (+ DT), or grafts depleted of cDC 
or Langerin+ DC.  Data show one representative experiment of 2.  Symbols 
represent individual mice and bars show the mean percentage of CD8+ HYDb 
Uty+ cells.  There is no statistically significant difference between groups. 
 
Figure 5. Activation of male-specific T cell responses is delayed in female mice 
receiving cDC-depleted hematopoietic grafts. 
A. Specific lysis of male target cells in the blood of female C57BL/6 mice 10 days 
after receiving splenocytes from wt or CD11c-DTR B6 males injected with DT 24 
hours previously.  Histograms are representative of the injection mix, and 
subsequent lysis of CFSE-labeled male (CFSE low) and female (CFSE high) 
splenocytes injected into non-depleted and cDC-depleted recipients.  The graph 
shows summary specific lysis data pooled from 2 independent experiments. ** p 
= < 0.01.  B. Expansion of male-specific HYDb Uty-specific CD8+ T cells in the 
blood of female C57BL/6 mice 10 days after receiving splenocytes from wt or 
CD11c-DTR B6 males injected with DT 24 hours previously.  Data are pooled 
from 2 independent experiments.  Bars show the mean percentage of CD8+ HYDb 
Uty+ cells ± s.e.m.  C. Specific lysis of male target cells in the spleen of female 
recipients 20 days after injection.  Data are representative of 2 independent 
experiments.  Symbols represent individual mice and bars show the mean 
specific lysis of male target cells. 
n.s.= not statistically significant. 
